Loading
A phase 1/2 trial of CRC01, Fludarabine, Cyclophosphamide in diffuse large b-cell lymphoma and follicular lymphoma, run by Curocell Inc., now recruiting.
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients is a phase 1/2 interventional study registered as NCT04836507 by Curocell Inc., with 91 participants planned, started 2021-03-02 and due to reach its primary completion in 2030-08-15. Interventions recorded: CRC01, Fludarabine, Cyclophosphamide. Conditions listed: Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal Large B-Cell Lymphoma (PMBCL). No results are recorded here; the registry entry is the source.
Shares Fludarabine, Follicular lymphoma, Cyclophosphamide, Diffuse large B-cell lymphoma.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Follicular lymphoma, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.